Viral inactivation of intramuscular immune serum globulins.
A new process for the production of intramuscular immunoglobulin products is described which includes viral inactivation through solvent-detergent treatment. Removal of solvent-detergent was accomplished by precipitation, filtration and diafiltration. Process-scale preparations had appropriate antibody potency levels, and improved IgG integrity relative to traditional IGIM products. Moreover, acceptable results were obtained in all in vitro and in vivo pre-clinical toxicology testing, as well as clinical evaluation. Scaled-down experiments demonstrated that the new process provides effective viral inactivation. Taken together, these results indicate that the new products should have the same efficacy of the previous IGIM products albeit with safety and processing improvements.
Alonso
W R
WR
Technology Department, Bayer Corporation, Clayton, NC 27520, USA. bill.alonso.b@bayer.com
Trukawinski
S
S
Savage
M
M
Tenold
R A
RA
Hammond
D J
DJ
D000907:Antibodies, Bacterial; D000914:Antibodies, Viral; D000998:Antiviral Agents / Q000494:pharmacology*; D002460:Cell Line; D003257:Consumer Product Safety; D004340:Drug Contamination / Q000517:prevention & control*; D015497:HIV-1 / Q000187:drug effects* / Q000254:growth & development; D006801:Humans; D007136:Immunoglobulins; D010755:Organophosphates / Q000494:pharmacology*; D020358:Sodium Cholate / Q000494:pharmacology*
D000907:Antibodies, Bacterial; D000914:Antibodies, Viral; D000998:Antiviral Agents; D007136:Immunoglobulins; D010755:Organophosphates; C009524:tributyl phosphate; D020358:Sodium Cholate